Long-Term Follow-up Study (LTFS)

Caribou Biosciences

Status: Invitation-only

Conditions: Hematologic Malignancy; Refractory B-Cell Non-Hodgkin Lymphoma; Relapsed/Refractory Multiple Myeloma; B-Cell Non-Hodgkin's Lymphoma; B Cell Lymphoma; Relapsed Non-Hodgkin Lymphoma; Relapsed/Refractory Acute Myeloid Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Non-Hodgkin Lymphoma

Treatments: Biological: Caribou-sponsored investigational therapy

Study type: Observational

Funder types: Industry

Identifiers

NCT05332054

LTFS

Details and patient eligibility

About

This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.

Full description

This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent (by patient or legal representative) obtained prior to study-specific activities/enrollment
• Completed a Caribou-sponsored study or was administered Caribou IP under a special access program or as part of an IIT
• Use of an effective method of birth control by women of childbearing potential and their partners and men with partners of childbearing potential (partners must also use an effective birth control method) through 12 months post IP infusion.

Exclusion criteria

• None

Trial design

150 participants in 1 patient group

Patients who received IP in a Caribou-sponsored, special access program or IIT and provided informed

Description:

consent for the LTFS

Treatment:

Biological: Caribou-sponsored investigational therapy